Tenderwize
Retour à la recherche

Non-exclusive discount agreement for Denosumab (Xgeva) products

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2027 · 337 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The structured data shows a submission deadline of 2027-07-31, while the notice text states the first participation dea...

Participation documents must be downloaded from the DTVP project room after access approval, but the annexes themselves...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements under §130a(8) SGB V for Denosumab/Xgeva products.
  • Products covered: Xgeva-branded products, biosimilars referencing the original Xgeva product, and corresponding import medicines.
Afficher le résumé complet

Open-house notice for non-exclusive discount agreements under §130a(8) SGB V for Denosumab/Xgeva-related products (including biosimilars and corresponding imports). The procedure is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no exclusivity. Documents are available via DTVP, but the extracted procurement documents were not provided beyond the TED XML notice, so document-specific annexes were not analyzed.

Risques

The structured data shows a submission deadline of 2027-07-31, while the notice text states the first participation dea...

Participation documents must be downloaded from the DTVP project room after access approval, but the annexes themselves...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of §4(18) AMG for the offered medicines.
  • The company must have its seat in Germany, another EU Member State, or another EEA Contracting State for the relevant medicines.

Eligibility

  • Submission of the completed declaration of no exclusion grounds is required.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive discount agreement for Denosumab (Xgeva) products

Supply lot for a non-exclusive discount agreement under §130a(8) SGB V covering medicinal products with the active substance Denosumab, limited to Xgeva-branded products, biosimilars referencing Xgeva, and corresponding import medicines. Open-house model; no exclusivity and no minimum purchase quantity guaranteed. Scope and lot information come from structured data and XML notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Aug 2026 - May 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jul 31, 2027

Détails de la procédure

Date de publication
05 Jul 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
464454-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30